Hlamulani Macebele

Public Health Specialist with over nine years of progressive experience supporting epidemiological research, programme evaluation, and evidence‑based policy development across clinical and public health programmes. Demonstrates strong expertise in centralized monitoring, quality improvement, and quality management to enhance programme performance, ensure data integrity, and support alignment with international best practices. Experienced in providing technical assistance and capacity building to multidisciplinary teams, including government and non-governmental partners, with a solid understanding of health systems, policy environments, and implementation challenges across diverse settings. Highly skilled in data management, monitoring and evaluation, and advanced statistical analysis using STATA and Power BI, with a proven ability to translate complex data into clear, actionable insights, policy briefs, and technical reports for decision‑makers. Brings demonstrated experience in grant and project support, performance monitoring, and strategic reporting to track progress against programme objectives. Adept at fostering cross‑sector collaboration, contributing to strategy development, and supporting high‑impact public health initiatives. Committed to upholding research ethics, regulatory compliance, and continuous quality improvement to drive effective, data‑driven public health action.

• Biostatistics in Public Health (STATA), Coursera, 2025-12-31
• The STATA OMNIBUS: Regression and Modelling with STATA., Coursera, 2025-12-31
• Biostatistics short course (introduction to R), HLB-SIMPLE, 2024-12-31
• Biostatistics short course (introduction to biostatistics, R), HLB-SIMPLE, 2024-12-31
• Comprehensive data analysis course using STATA, CESAR, 2021-12-31

Co-authored: Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): Week 48 results from a randomized, multicenter, open-label, non-inferiority trial., https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00289-5/fulltext

Abstract 1: Impact of maternal dolutegravir (DTG) use on the growth of infants during the first 18 months of life. Oral Presentation at #INTEREST2025 on the 14th of May 2025.

Abstract 2: Factors associated with Antiretroviral Therapy (ART) non-adherence among treatment-naïve adult trial participants in South Africa: a pooled analysis of the ADVANCE and Opti-DOR trials. Poster Presentation at #INTEREST2026 on the 12th of May 2026.

• A randomised, open label switch study comparing darunavir/ritonavir 800mg daily with lopinavir/ritonavir 800mg/200mg daily, in HIV-positive participants., WRHI052, Data Capture / project administrator, Completed, 2017-2019
• A 96-week Randomised, Phase 3 Non-inferiority Study of DTG+TAF+FTC Compared with DTG+TDF+FTC and EFV+TDF+FTC in Patients Infected with HIV-1 Starting First-line Antiretroviral Therapy (ADVANCE), WRHI060, Quality Improvement Advisor, Completed, 2017-2020
• A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared with DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected with HIV-1 Starting First-line Antiretroviral Therapy – Extension to 192 weeks (ADVANCE extension), WRHI 060, Data Manager, Completed, 2020-2023
• COHIVE: COVID-19 in people living with HIV Evaluation of Risk Factors and Outcomes in resource-limited settings -a pooled sub study of ADVANCE, D2EFT, DolPHIN2, and NAMSAL., EZ060-COHIVE, Quality Improvement Advisor, Completed, 2020-2021
• A phase 2, exploratory, single center, randomized, open label, adaptive clinical trial to compare the safety and efficacy of four different experimental drug regimens to standard of care for the treatment of symptomatic outpatients with COVID-19 (react), SP-PA-COV-202, Quality Improvement Advisor, Completed, 2020-2021
• A multi-center, randomized, open label study of nitazoxanide (NTZ), or sofosbuvir and daclatasvir (SOF/DCV), compared to no pharmacological intervention for the prevention of COVID-19 disease in healthcare workers at high risk of exposure to SARS-CoV-2, EZ-SS-025, Quality Improvement Advisor, Completed, 2020-2022
• A single arm, phase 3 study, exploring the safety of doravirine-based first-line antiretroviral therapy for women of reproductive potential living with HIV, a pilot switch study strategy in South Africa, EZMiM017, Quality Improvement Advisor, Completed, 2020-2022
• A single-arm, phase 3, pilot study investigating the efficacy of DORavirine in adults living with HIV experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance, EZMiM018, Quality Improvement Advisor, Completed, 2020-2022
• A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxanide (NTZ) Versus Placebo in SARS-CoV-2 Virus Infected Participants., DuACT-101, Quality Improvement Advisor, Completed, 2020-2022
• A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa, TMC278LAHTX3002, Data Manager, Completed, 2021-2025
• A randomised, multi-centre, double-blind, Phase 3 study to observe the effectiveness, safety and tolerability of molnupiravir compared to placebo administered orally to high-risk adult outpatients with mild COVID-19 receiving local standard of care in South Africa, EZ-SS-029, Data Manager, Completed, 2022-2024
• A Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy, MK-8591A - 051, Data Manager, Ongoing, 2023-2023
• A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants, MK-8591A - 053, Data Manager, Ongoing, 2023-2023
• A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study, MK-8591A - 054, Data Manager, Ongoing, 2023-2023
• Utilizing private pharmacies to initiate high risk young women and men on pre-exposure prophylaxis (PrEP) in South Africa, EZ-FV-032, Data Manager, Ongoing, 2023-2023
• A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF compared to DTG/TAF/FTC in Participants Infected with HIV-1 Starting First-line Antiretroviral Therapy (Opti-Dor), EZ-JW-033, Data Manager, Ongoing, 2023-2023
• The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once weekly in participants with established cardiovascular disease (REDEFINE), NN9838-494, Data Manager, Ongoing, 2023-2023
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults (TB Vaccine), MRI-TBV02-301, Data Manager, Ongoing, 2024-2024
• A randomized, open-label, multicentre, active-controlled study to evaluate the safety and efficacy of FDC tablets containing BIC 75 mg/LEN 50 mg versus SBR in people with HIV-1 who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a SBR for at least 6 months prior to screening (GILEAD), GS-US-621-6289, Data Manager, Ongoing, 2024-2024
• A Phase 3b, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies (CARLA), TMC278LAHTX4002, Data Manager, Ongoing, 2025-2025
• Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial: A two-phase single-arm interventional (i.e. TLD) study to identify the optimally safe and effective ART regimen for individuals with newly detected HIV infection after recent CAB-LA PrEP exposure. (PICASSO), EZ-BB-036, Data Manager, Ongoing, 2025-2025